Format
Sort by
Items per page

Send to

Choose Destination

Best matches for oncolytic coxsackievirus:

Search results

Items: 1 to 20 of 118

1.

Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: focus on fiber chimerism and mosaicism, hexon and pIX.

Stepanenko AA, Chekhonin VP.

Virus Res. 2018 Aug 17. pii: S0168-1702(18)30413-1. doi: 10.1016/j.virusres.2018.08.012. [Epub ahead of print] Review.

PMID:
30125593
2.

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.

Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H.

Mol Ther Oncolytics. 2018 Feb 14;9:1-12. doi: 10.1016/j.omto.2018.02.001. eCollection 2018 Jun 29.

3.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

4.

Secretome Screening Reveals Fibroblast Growth Factors as Novel Inhibitors of Viral Replication.

van Asten SD, Raaben M, Nota B, Spaapen RM.

J Virol. 2018 Jun 13. pii: JVI.00260-18. doi: 10.1128/JVI.00260-18. [Epub ahead of print]

PMID:
29899088
5.

Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.

Hazini A, Pryshliak M, Brückner V, Klingel K, Sauter M, Pinkert S, Kurreck J, Fechner H.

Hum Gene Ther. 2018 Jun 20. doi: 10.1089/hum.2018.036. [Epub ahead of print]

PMID:
29739251
6.

Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.

Lin Y, Wang W, Wan J, Yang Y, Fu W, Pan D, Cai L, Cheng T, Huang X, Wang Y.

Virol J. 2018 Apr 10;15(1):65. doi: 10.1186/s12985-018-0975-x.

7.

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF.

Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018.

PMID:
29399408
8.

Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.

Garza-Morales R, Yaddanapudi K, Perez-Hernandez R, Riedinger E, McMasters KM, Shirwan H, Yolcu E, Montes de Oca-Luna R, Gomez-Gutierrez JG.

Cancer Biol Ther. 2018 Mar 4;19(3):188-197. doi: 10.1080/15384047.2017.1416274. Epub 2018 Jan 22.

PMID:
29252087
9.

Traveling treatment: medical tourism in the emerging era of potentially transmissible therapeutics.

Hreh M, Cohn CS, McKenna D, Gniadek TJ.

Transfusion. 2017 Oct;57(10):2549-2550. doi: 10.1111/trf.14276. No abstract available.

PMID:
28944545
10.

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.

Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaan4220. doi: 10.1126/scitranslmed.aan4220.

11.

Oncolytic coxsackievirus therapy as an immunostimulator.

Miyamoto S, Sagara M, Kohara H, Tani K.

Rinsho Ketsueki. 2017;58(8):977-982. doi: 10.11406/rinketsu.58.977. Review. Japanese.

PMID:
28883283
12.

Systemic virotherapy for multiple myeloma.

Oliva S, Gambella M, Boccadoro M, Bringhen S.

Expert Opin Biol Ther. 2017 Nov;17(11):1375-1387. doi: 10.1080/14712598.2017.1364359. Epub 2017 Aug 10. Review.

PMID:
28796556
13.

Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines.

Svyatchenko VA, Ternovoy VA, Kiselev NN, Demina AV, Loktev VB, Netesov SV, Chumakov PM.

Arch Virol. 2017 Nov;162(11):3355-3362. doi: 10.1007/s00705-017-3492-0. Epub 2017 Aug 1.

PMID:
28766058
14.

Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Foreman PM, Friedman GK, Cassady KA, Markert JM.

Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Review.

15.

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter.

Bhatia S, O'Bryan SM, Rivera AA, Curiel DT, Mathis JM.

Oncolytic Virother. 2016 Nov 11;5:99-113. eCollection 2016.

16.

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK.

Oncotarget. 2016 Nov 29;7(48):79828-79841. doi: 10.18632/oncotarget.12975.

17.

Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses.

Sosnovtseva AO, Lipatova AV, Grinenko NF, Baklaushev VP, Chumakov PM, Chekhonin VP.

Bull Exp Biol Med. 2016 Oct;161(6):821-825. Epub 2016 Oct 26.

PMID:
27783287
18.

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.

Alberts P, Olmane E, Brokāne L, Krastiņa Z, Romanovska M, Kupčs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D.

APMIS. 2016 Oct;124(10):896-904. doi: 10.1111/apm.12576. Epub 2016 Jul 26.

PMID:
27457663
19.

The Role of Intralesional Therapies in Melanoma.

Agarwala SS.

Oncology (Williston Park). 2016 May;30(5):436-41. Review.

20.

Therapeutic Use of Native and Recombinant Enteroviruses.

Ylä-Pelto J, Tripathi L, Susi P.

Viruses. 2016 Feb 23;8(3):57. doi: 10.3390/v8030057. Review.

Supplemental Content

Loading ...
Support Center